NCT03500822

Brief Summary

The aim of this study is to identify whether actively induced dynamic hyperinflation can cause left-ventricular diastolic dysfunction in healthy male subjects in order to explore the mechanisms of developing cardiac dysfunctions in patients with COPD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2016

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 29, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 9, 2018

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 18, 2018

Completed
Last Updated

April 18, 2018

Status Verified

April 1, 2018

Enrollment Period

10 months

First QC Date

February 9, 2018

Last Update Submit

April 15, 2018

Conditions

Keywords

dynamic hyperinflationdiastolic dysfunctionCOPDChronic Obstructive Pulmonary DiseaseMetronome-paced TachypneaExpiratory-stenosis Breathing

Outcome Measures

Primary Outcomes (1)

  • E/A-ratio (absolute change between tidal breathing and smallest stenosis)

    E/A-ratio will be measured by transthoracic echocardiography (Vivid S9, general electric healthcare, Fairfield, USA) according to the valid standards of The European Association of Echocardiography. This parameter represents the left-ventricular diastolic function.

    At the end of each cycle - tidal breathing as well as hyperinflation-intervention (each cycle is at least 90 seconds).

Secondary Outcomes (6)

  • E/E'-ratio

    At the end of each cycle - tidal breathing as well as hyperinflation-intervention (each cycle is at least 90 seconds).

  • deceleration time of the E-wave transmitral (msec)

    At the end of each cycle - tidal breathing as well as hyperinflation-intervention (each cycle is at least 90 seconds).

  • Maximal diastolic transtricuspid flow (m/sec)

    At the end of each cycle - tidal breathing as well as hyperinflation-intervention (each cycle is at least 90 seconds).

  • Maximal late-systolic velocity of the lateral tricuspid valve in Tissue Doppler Imaging (cm/sec)

    At the end of each cycle - tidal breathing as well as hyperinflation-intervention (each cycle is at least 90 seconds).

  • Inspiratory Capacity

    At the end of each cycle - tidal breathing as well as hyperinflation-intervention (each cycle is at least 90 seconds).

  • +1 more secondary outcomes

Study Arms (2)

Metronome-paced tachypnea

EXPERIMENTAL

Dynamic hyperinflation by the method of metronome-paced tachypnea.

Procedure: Metronome-paced tachypnea

Exspiratory-stenosis breathing

EXPERIMENTAL

Dynamic hyperinflation by the method of expiratory-stenosis breathing.

Procedure: Expiratory-stenosis breathing

Interventions

three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2

Also known as: MPT
Metronome-paced tachypnea

three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm

Also known as: ESB
Exspiratory-stenosis breathing

Eligibility Criteria

Age18 Years - 40 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI \<27 kg/m2
  • Lifelong nonsmoker (currently non-smoking and up to now less than 100 cigarettes)

You may not qualify if:

  • Obstructive pulmonary diseases (asthma, COPD)
  • Cardiovascular diseases (cardiac insufficiency, coronary heart diseases, hypertonia)
  • Other relevant pulmonary or cardiac diseases
  • Baseline E/A-ratio \<1

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Otto Wagner Spital, Dep. of Respiratory and Critical Care Medicine

Vienna, 1140, Austria

Location

Related Publications (9)

  • Cooper CB, Calligaro GL, Quinn MM, Eshaghian P, Coskun F, Abrazado M, Bateman ED, Raine RI. Determinants of dynamic hyperinflation during metronome-paced tachypnea in COPD and normal subjects. Respir Physiol Neurobiol. 2014 Jan 1;190:76-80. doi: 10.1016/j.resp.2013.08.002. Epub 2013 Aug 27.

    PMID: 23994176BACKGROUND
  • Weigt SS, Abrazado M, Kleerup EC, Tashkin DP, Cooper CB. Time course and degree of hyperinflation with metronome-paced tachypnea in COPD patients. COPD. 2008 Oct;5(5):298-304. doi: 10.1080/15412550802363428.

    PMID: 18972278BACKGROUND
  • Evangelista A, Flachskampf F, Lancellotti P, Badano L, Aguilar R, Monaghan M, Zamorano J, Nihoyannopoulos P; European Association of Echocardiography. European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. Eur J Echocardiogr. 2008 Jul;9(4):438-48. doi: 10.1093/ejechocard/jen174.

    PMID: 18579482BACKGROUND
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.

    PMID: 16055882BACKGROUND
  • Akoumianaki E, Maggiore SM, Valenza F, Bellani G, Jubran A, Loring SH, Pelosi P, Talmor D, Grasso S, Chiumello D, Guerin C, Patroniti N, Ranieri VM, Gattinoni L, Nava S, Terragni PP, Pesenti A, Tobin M, Mancebo J, Brochard L; PLUG Working Group (Acute Respiratory Failure Section of the European Society of Intensive Care Medicine). The application of esophageal pressure measurement in patients with respiratory failure. Am J Respir Crit Care Med. 2014 Mar 1;189(5):520-31. doi: 10.1164/rccm.201312-2193CI.

    PMID: 24467647BACKGROUND
  • Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9. doi: 10.1164/rccm.2110093.

    PMID: 12153966BACKGROUND
  • Lopez-Sanchez M, Munoz-Esquerre M, Huertas D, Gonzalez-Costello J, Ribas J, Manresa F, Dorca J, Santos S. High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS One. 2013 Jun 27;8(6):e68034. doi: 10.1371/journal.pone.0068034. Print 2013.

    PMID: 23826360BACKGROUND
  • Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010 Jan 21;362(3):217-27. doi: 10.1056/NEJMoa0808836.

    PMID: 20089972BACKGROUND
  • Urban MH, Mayr AK, Schmidt I, Grasmuk-Siegl E, Burghuber OC, Funk GC. Effects of Dynamic Hyperinflation on Left Ventricular Diastolic Function in Healthy Subjects - A Randomized Controlled Crossover Trial. Front Med (Lausanne). 2021 May 4;8:659108. doi: 10.3389/fmed.2021.659108. eCollection 2021.

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Georg C Funk, Assoc. Prof.

    Department of Respiratory and Critical Care Medicine and Ludwig-Boltzmann Institute for COPD and Respiratory Epidemiology, Otto Wagner Hospital, Vienna

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Intensive Care Unit, Principal Investigator

Study Record Dates

First Submitted

February 9, 2018

First Posted

April 18, 2018

Study Start

November 1, 2016

Primary Completion

September 1, 2017

Study Completion

September 29, 2017

Last Updated

April 18, 2018

Record last verified: 2018-04

Locations